Infection of H. pylori is associated with peptic ulcer disease, gastric adenocarcinoma, and mucosa associated lymphoid tissue (MALT) lymphoma. Today, it is estimated that over 50% of the world’s population is infected with the bacteria. The World Health Organization categorizes H. pylori as a group I or definite human carcinogen. Over the course of the last few years, testing for H. pylori in symptomatic patients has become standard practice.
The BreathID System is intended for use in the qualitative detection of urease associated with Helicobacter pylori in the human stomach and as an aid in initial diagnosis and post treatment monitoring of H. pylori infection in adult patients. Urea Breath Tests are well established as reliable, non-invasive methods for detecting H. pylori. They are highly endorsed by various medical societies as the test of choice for initial detection as well as for post-treatment testing. The BreathID Breath Test System has been used for many years outside the U.S. With exceptional sensitivity of 100% and specificity of 99.2%, this system features accuracy that is unmatched by traditional H. pylori tests currently available, ensuring you can have full confidence in the results you receive.